1.Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011;343:d3897.
2.Woo Baidal JA, Lavine JE. The intersection of nonalcoholic fatty liver disease and obesity. Science translational medicine. 2016;8(323):323rv1.
3.Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md). 2016;64(1):73–84.
4.Duseja A, Chalasani N. Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD). Hepatology international. 2013;7 Suppl 2:755–64.
5.Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition (Burbank, Los Angeles County, Calif). 2004;20(1):63–8.
6.Wang G, Walker SO, Hong X, Bartell TR, Wang X. Epigenetics and early life origins of chronic noncommunicable diseases. The Journal of adolescent health: official publication of the Society for Adolescent Medicine. 2013;52(2 Suppl 2):S14–21.
7.Jiang X, Ma H, Wang Y, Liu Y. Early life factors and type 2 diabetes mellitus. Journal of diabetes research. 2013;2013:485082.
8.Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Current pharmaceutical design. 2010;16(17):1941–51.
9.Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, et al. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PloS one. 2012;7(8):e44136.
10.Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, Lugara M, et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I. The Journal of clinical endocrinology and metabolism. 2011;96(10):E1640–4.
11.Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. European journal of endocrinology. 2012;167(1):67–74.
12.Li M, Reynolds CM, Segovia SA, Gray C, Vickers MH. Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. BioMed research international. 2015;2015:437107.
13.Taback SP, Collu R, Deal CL, Guyda HJ, Salisbury S, Dean HJ, et al. Does growth-hormone supplementation affect adult height in Turner’s syndrome? Lancet (London, England). 1996;348(9019):25–7.
14.Silventoinen K. Determinants of variation in adult body height. Journal of biosocial science. 2003;35(2):263–85.
15.Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. Bmj. 2011;342:c7157.
16.Lin-Su K, Harbison MD, Lekarev O, Vogiatzi MG, New MI. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. The Journal of clinical endocrinology and metabolism. 2011;96(6):1710–7.
17.Gu Y, Li H, Bao X, Zhang Q, Liu L, Meng G, et al. The Relationship Between Thyroid Function and the Prevalence of Type 2 Diabetes Mellitus in Euthyroid Subjects. The Journal of clinical endocrinology and metabolism. 2017;102(2):434–42.
18.Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. Journal of diabetes. 2013;5(4):406–15.
19.Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.
20.Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607–13.
21.Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C, et al. Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. Diabetes care. 2017;40(1):109–16.
22.Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (Baltimore, Md). 2012;56(3):943–51.
23.Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive value of having positive family history of cardiovascular disorders, diabetes mellitus, dyslipidemia, and hypertension in non-alcoholic fatty liver disease patients. Acta medica Iranica. 2013;51(5):307–13.
24.Lorenzo C, Williams K, Stern MP, Haffner SM. Height, ethnicity, and the incidence of diabetes: the San Antonio Heart Study. Metabolism: clinical and experimental. 2009;58(11):1530–5.
25.Janghorbani M, Momeni F, Dehghani M. Hip circumference, height and risk of type 2 diabetes: systematic review and meta-analysis. Obesity reviews: an official journal of the International Association for the Study of Obesity. 2012;13(12):1172–81.
26.Vangipurapu J, Stancakova A, Jauhiainen R, Kuusisto J, Laakso M. Short Adult Stature Predicts Impaired beta-Cell Function, Insulin Resistance, Glycemia, and Type 2 Diabetes in Finnish Men. The Journal of clinical endocrinology and metabolism. 2017;102(2):443–50.
27.Yang C, Yang S, Xu W, Zhang J, Fu W, Feng C. Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. PloS one. 2017;12(5):e0177249.
28.Takahashi Y. Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. Endocrine journal. 2012;59(11):955–62.
29.Ahrens M, Ammerpohl O, von Schonfels W, Kolarova J, Bens S, Itzel T, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell metabolism. 2013;18(2):296–302.
30.Ouni M, Gunes Y, Belot MP, Castell AL, Fradin D, Bougneres P. The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth. Clinical epigenetics. 2015;7:22.
31.Holland ML, Lowe R, Caton PW, Gemma C, Carbajosa G, Danson AF, et al. Early-life nutrition modulates the epigenetic state of specific rDNA genetic variants in mice. Science (New York, NY). 2016;353(6298):495–8.
32.Pruis MG, Lendvai A, Bloks VW, Zwier MV, Baller JF, de Bruin A, et al. Maternal western diet primes non-alcoholic fatty liver disease in adult mouse offspring. Acta physiologica (Oxford, England). 2014;210(1):215–27.
33.Tyrrell J, Jones SE, Beaumont R, Astley CM, Lovell R, Yaghootkar H, et al. Height, body mass index, and socioeconomic status: mendelian randomisation study in UK Biobank. Bmj. 2016;352:i582.
34.Kennedy BP, Kawachi I, Glass R, Prothrow-Stith D. Income distribution, socioeconomic status, and self rated health in the United States: multilevel analysis. Bmj. 1998;317(7163):917–21.
35.Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745–50.